arrow_back Back to App

Improved Healthcare for Sickle Cell Disease Patients

This act establishes a demonstration project to enhance access to high-quality outpatient care for individuals with sickle cell disease, particularly young adults and pregnant women. The program aims to improve treatment coordination, access to specialists, and mental health and social support services, ultimately reducing healthcare costs and improving patients' quality of life.
Key points
A 5-year demonstration project will improve medical care for individuals with sickle cell disease, including young adults and pregnant women.
Participating states will receive financial support to create care teams, identify treatment barriers, and implement best practices.
Sickle cell disease patients will gain better access to medications, pain management, specialists, mental health services, and medical transportation.
States will receive 100% reimbursement for sickle cell disease treatment costs under the program, encouraging investment in better care.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_3389
Sponsor: Sen. Booker, Cory A. [D-NJ]
Process start date: 2021-12-14
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Sickle Cell Disease Comprehensive Care Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_3389.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-12-14.

What are the main provisions?

Key points include:

  • A 5-year demonstration project will improve medical care for individuals with sickle cell disease, including young adults and pregnant women.
  • Participating states will receive financial support to create care teams, identify treatment barriers, and implement best practices.
  • Sickle cell disease patients will gain better access to medications, pain management, specialists, mental health services, and medical transportation.
  • States will receive 100% reimbursement for sickle cell disease treatment costs under the program, encouraging investment in better care.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Booker, Cory A. [D-NJ].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health Benefits